Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases

To compare the incidence of diabetic ketoacidosis (DKA) among patients with type 2 diabetes mellitus (T2DM) who were new users of sodium glucose co‐transporter 2 inhibitors (SGLT2i) versus other classes of antihyperglycemic agents (AHAs).

• Publication year

  2019

• Venue

  Pharmacoepidemiology and Drug Safety

• Publication date

  2019-08-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pds.4887PMID 31456304PMCID 6916409
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

  2019cited by this paper
• Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases

  2019cited by this paper
• RE: DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.

  2018cited by this paper
• Sodium‐glucose co‐transporter‐2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population‐based cohort study

  2018influential reference
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.

  2017cited by this paper
• Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

  2017cited by this paper
• Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium–Glucose Cotransporter 2 Inhibitors—A Nationwide, Retrospective Cohort Study, 1995–2014

  2017cited by this paper
• Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents.

  2017cited by this paper
• Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.

  2017cited by this paper
• Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review

  2017cited by this paper
• DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.

  2017cited by this paper
• Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials

  2017cited by this paper
• Practical considerations for the use of sodium–glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes

  2016cited by this paper
• Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials

  2016cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• SGLT inhibition and euglycaemic diabetic ketoacidosis.

  2015cited by this paper
• Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

  2015cited by this paper
• Feasibility and utility of applications of the common data model to multiple, disparate observational health databases

  2015cited by this paper
• Management of adult diabetic ketoacidosis

  2014cited by this paper
• R: A language and environment for statistical computing.

  2014cited by this paper
• International Diabetes Federation.

  2013cited by this paper
• Interpreting observational studies: why empirical calibration is needed to correct p-values

  2013cited by this paper
• Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model

  2012cited by this paper
• One‐to‐many propensity score matching in cohort studies

  2012cited by this paper
• Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies

  2010cited by this paper
• Hyperglycemic Crises in Adult Patients With Diabetes

  2009cited by this paper
• Ketoacidosis occurs in both Type 1 and Type 2 diabetes— a population‐based study from Northern Sweden

  2008cited by this paper
• Large-Scale Bayesian Logistic Regression for Text Categorization

  2007cited by this paper
• Regression Shrinkage and Selection via the Lasso

  1996cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper

• GLP- 1 Receptor Agonists in Patients with Cancer are Associated with Reduced All-Cause Mortality and Hospitalization.

  2026cites this paper
• Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population.

  2026cites this paper
• Hypoglycemic effects of methanolic extract of lemon verbena in streptozotocin-induced diabetic rats

  2025cites this paper
• Preoperative SGLT2 Inhibitor Use and Postoperative Diabetic Ketoacidosis.

  2025cites this paper
• Clinical and prognostic differences in diabetic ketoacidosis between type 2 and type 1 diabetes.

  2025cites this paper
• A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus

  2025influential citation
• Diabetic Ketoacidosis Caused by Acute Pancreatitis Results in Severe Hypertriglyceridemia: A Case Report

  2025cites this paper
• Incidence of sodium–glucose cotransporter-2 inhibitor-associated perioperative ketoacidosis in surgical patients: a prospective cohort study

  2024influential citation
• The necessity of validity diagnostics when drawing causal inferences from observational data: lessons from a multi-database evaluation of the risk of non-infectious uveitis among patients exposed to Remicade®

  2024cites this paper
• Use of Sensitivity Analyses to Assess Uncontrolled Confounding from Unmeasured Variables in Observational, Active Comparator Pharmacoepidemiologic Studies: A Systematic Review.

  2024cites this paper
• Reduced Rate of Hospitalizations for Acute Diabetes Events Before and After FreeStyle Libre® System Initiation in Some People With Type 2 Diabetes on Insulin-Secretagogue Oral Drug Therapy Without Insulin in France

  2024influential citation
• Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk

  2024cites this paper
• Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts

  2024cites this paper
• Investigation of hepatic adverse events due to quetiapine by using the common data model

  2023cites this paper
• Methods for the Inclusion of Real-World Evidence in a Rare Events Meta-Analysis of Randomized Controlled Trials

  2023influential citation
• Diabetic ketoacidosis with SGLT2 inhibitor use - a patient series.

  2023cites this paper
• Research Progress of SGLT2 Inhibitors in the Treatment of Heart Failure Complicated with Atrial Fibrillation

  2023cites this paper
• Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post-Authorisation Safety Study

  2023cites this paper
• Severe euglycemic diabetic ketoacidosis secondary to sodium-glucose co-transporter 2 inhibitor: case report and literature review

  2023cites this paper
• A case series of diabetic ketoacidosis associated with SGLT2 inhibitors

  2023cites this paper
• An Overview of the Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Hematological Parameters in Diabetic Patients

  2023cites this paper
• Comparison of statistical methods for integrating real‐world evidence in a rare events meta‐analysis of randomized controlled trials

  2023cites this paper
• Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies

  2023cites this paper
• Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis.

  2023cites this paper
• The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?

  2023cites this paper
• Phytochemical profile and antidiabetic effect of the bioactive fraction of Cirsium setidens in streptozotocin-induced type 2 diabetic mice

  2022cites this paper
• Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.

  2022cites this paper
• Dietary Polyphenols as Natural Inhibitors of α-Amylase and α-Glucosidase

  2022cites this paper
• Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus

  2022cites this paper
• Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data

  2022cites this paper
• Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies

  2022cites this paper
• Relationship of concomitant anti-diabetic drug administration with sodium-glucose co-transporter 2 inhibitor-related ketosis

  2022cites this paper
• WICOX: Weight-Based Integrated Cox Model for Time-to-Event Data in Distributed Databases Without Data-Sharing

  2022cites this paper
• Increasing Sodium-Glucose Cotransporter 2 Inhibitor Use in CKD: Perspectives and Presentation of a Clinical Pathway

  2022cites this paper
• Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors and The Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events.

  2021cites this paper
• RESEARCH PROTOCOL: Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus

  2021cites this paper
• Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes

  2021cites this paper
• Recent Advances in Sodium Glucose Cotransporter-2 Inhibitors

  2021cites this paper
• A Fatal Case of Hypertriglyceridemia-Induced Acute Pancreatitis in a Patient With Diabetic Ketoacidosis

  2021cites this paper
• Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71,553 Individuals.

  2021cites this paper
• Polyphenolic inhibition of enterocytic starch digestion enzymes and glucose transporters for managing type 2 diabetes may be reduced in food systems

  2021cites this paper
• Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis

  2020cites this paper
• Euglycemic Ketoacidosis

  2020cites this paper
• Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

  2020cites this paper
• Diabetic ketoacidosis with SGLT2 inhibitors

  2020cites this paper
• Heart failure in diabetes mellitus: an updated review.

  2020cites this paper
• Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the Bad

  2020cites this paper
• Table of Contents

  2020cites this paper
• Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases

  2019cites this paper
• Total phenolic content and anti - diabetic activity of dried and fresh leaves of Ocimum sanctum (Linn)

  year unknowncites this paper